Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.034 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0169 | 0.1841 | 0.5 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.021 | 0.3805 | 0.2407 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0169 | 0.1841 | 0.5 |
Schistosoma mansoni | cathepsin D (A01 family) | 0.0296 | 0.7922 | 0.7453 |
Loa Loa (eye worm) | hypothetical protein | 0.034 | 1 | 1 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.021 | 0.3805 | 0.3805 |
Entamoeba histolytica | type A flavoprotein, putative | 0.013 | 0 | 0.5 |
Schistosoma mansoni | cathepsin D (A01 family) | 0.0296 | 0.7922 | 0.7453 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.034 | 1 | 1 |
Treponema pallidum | flavodoxin | 0.013 | 0 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.0301 | 0.8159 | 0.5 |
Brugia malayi | FAD binding domain containing protein | 0.034 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.034 | 1 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.013 | 0 | 0.5 |
Leishmania major | p450 reductase, putative | 0.034 | 1 | 1 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.034 | 1 | 1 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0301 | 0.8159 | 0.5 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.034 | 1 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.034 | 1 | 1 |
Schistosoma mansoni | cytochrome P450 reductase | 0.034 | 1 | 1 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.034 | 1 | 1 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.034 | 1 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.013 | 0 | 0.5 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.034 | 1 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.013 | 0 | 0.5 |
Leishmania major | cytochrome P450 reductase, putative | 0.0301 | 0.8159 | 0.8159 |
Entamoeba histolytica | type A flavoprotein, putative | 0.013 | 0 | 0.5 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.034 | 1 | 0.5 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.034 | 1 | 1 |
Chlamydia trachomatis | sulfite reductase | 0.021 | 0.3805 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.034 | 1 | 1 |
Plasmodium vivax | flavodoxin domain containing protein | 0.0301 | 0.8159 | 0.8159 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0171 | 0.1964 | 0.0151 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.034 | 1 | 1 |
Trypanosoma cruzi | p450 reductase, putative | 0.034 | 1 | 1 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.034 | 1 | 1 |
Brugia malayi | FAD binding domain containing protein | 0.021 | 0.3805 | 0.3805 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.034 | 1 | 1 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.034 | 1 | 1 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.034 | 1 | 1 |
Trichomonas vaginalis | NADPH fad oxidoreductase, putative | 0.0301 | 0.8159 | 0.8159 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | = 75 % | Effect on the cell cycle of L1210 cells and expressed as percent of L1210 cells in G2+M phases at 5 uM concentration | ChEMBL. | 11882002 |
Activity (functional) | = 75 % | Effect on the cell cycle of L1210 cells and expressed as percent of L1210 cells in G2+M phases at 5 uM concentration | ChEMBL. | 11882002 |
IC50 (functional) | = 0.8 uM | Antiproliferative activity in vitro against K-562 (human leukemia) cell line. | ChEMBL. | 11882002 |
IC50 (functional) | = 0.8 uM | Antiproliferative activity in vitro against K-562 (human leukemia) cell line. | ChEMBL. | 11882002 |
IC50 (functional) | = 1.3 uM | Antiproliferative activity tested in vitro against L1210 (murine leukemia) cell line. | ChEMBL. | 11882002 |
IC50 (functional) | = 1.3 uM | Antiproliferative activity tested in vitro against L1210 (murine leukemia) cell line. | ChEMBL. | 11882002 |
IC50 (functional) | = 3.3 uM | Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line. | ChEMBL. | 11882002 |
IC50 (functional) | = 3.3 uM | Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line. | ChEMBL. | 11882002 |
IC50 (functional) | = 3.5 uM | Antiproliferative activity in vitro against HT-29 (human colon carcinoma) cell line. | ChEMBL. | 11882002 |
IC50 (functional) | = 3.5 uM | Antiproliferative activity in vitro against HT-29 (human colon carcinoma) cell line. | ChEMBL. | 11882002 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Mus musculus | ChEMBL23 | 11882002 | |
Homo sapiens | ChEMBL23 | 11882002 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.